AntriaBio Stock Price, News & Analysis (OTCMKTS:ANTB)

$0.82 0.02 (2.50 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$0.81
Today's Range$0.79 - $0.82
52-Week Range$0.75 - $1.25
Volume11,180 shs
Average Volume4,125 shs
Market Capitalization$47.55 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.41

About AntriaBio (OTCMKTS:ANTB)

AntriaBio, Inc. is a biopharmaceutical company. The Company develops sustained release injectable therapies. The Company's products include AB101 and AB301. The Company's lead product candidate, AB101, is a microsphere formulation of PEGylated human recombinant insulin, is being developed as an extended acting basal insulin intended for once-weekly subcutaneous injection, for use alone and in combination with bolus prandial insulin or oral glucose lowering therapies, to improve glycemic control in patients with Type 1 and Type 2 Diabetes Mellitus. It has conducted pre-clinical studies, including acute and sub-acute toxicity studies in two species, safety pharmacology, and mutagenicity/genotoxicity studies. Its product candidate, AB301, is a once-weekly injectable combination of a pegylated human glucagon-like peptide-1 (GLP-1) agonist and AB101, the Company's basal insulin lead product candidate. The Company is engaged in additional ongoing preclinical studies of AB301.

Receive ANTB News and Ratings via Email

Sign-up to receive the latest news and ratings for ANTB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ANTB
CUSIPN/A
Phone303-222-2128

Debt

Debt-to-Equity RatioN/A
Current Ratio2.58%
Quick Ratio2.58%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.18 per share
Price / Book4.56

Profitability

Trailing EPS($0.82)
Net Income$-20,270,000.00
Net MarginsN/A
Return on Equity-283.13%
Return on Assets-225.17%

Miscellaneous

Employees50
Outstanding Shares53,730,000

AntriaBio (OTCMKTS:ANTB) Frequently Asked Questions

What is AntriaBio's stock symbol?

AntriaBio trades on the OTCMKTS under the ticker symbol "ANTB."

Who are some of AntriaBio's key competitors?

Who are AntriaBio's key executives?

AntriaBio's management team includes the folowing people:

  • Nevan C. Elam, Chairman of the Board, President, Chief Executive Officer (Age 49)
  • Morgan Fields, Chief Accounting Officer (Age 34)
  • Sankaram Mantripragada Ph.D., Chief Scientific Officer (Age 55)
  • Gilbert M. Labrucherie J.D., Director (Age 45)
  • David F. Welch Ph.D., Director (Age 56)
  • Hoyoung Huh Ph.D., Independent Director (Age 48)
  • Tae Hoon Kim, Independent Director
  • Samir Patel, Independent Director

How do I buy AntriaBio stock?

Shares of AntriaBio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AntriaBio's stock price today?

One share of AntriaBio stock can currently be purchased for approximately $0.82.

How big of a company is AntriaBio?

AntriaBio has a market capitalization of $47.55 million. The biopharmaceutical company earns $-20,270,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. AntriaBio employs 50 workers across the globe.

How can I contact AntriaBio?

AntriaBio's mailing address is 1450 INFINITE DRIVE, LOUISVILLE CO, 80027. The biopharmaceutical company can be reached via phone at 303-222-2128 or via email at [email protected]


MarketBeat Community Rating for AntriaBio (ANTB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  16 (Vote Underperform)
Total Votes:  33
MarketBeat's community ratings are surveys of what our community members think about AntriaBio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AntriaBio (OTCMKTS:ANTB) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for AntriaBio (OTCMKTS:ANTB)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

AntriaBio (OTCMKTS:ANTB) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for AntriaBio (OTCMKTS:ANTB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

AntriaBio (OTCMKTS ANTB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 38.30%
Insider Trades by Quarter for AntriaBio (OTCMKTS:ANTB)

AntriaBio (OTCMKTS ANTB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/6/2017David F WelchDirectorBuy5,000$0.95$4,750.00View SEC Filing  
2/9/2017David F WelchDirectorBuy13,100$0.98$12,838.00View SEC Filing  
1/20/2017David F WelchDirectorBuy24,983$1.01$25,232.83View SEC Filing  
1/12/2017David F WelchDirectorBuy5,000$0.95$4,750.00View SEC Filing  
1/11/2017David F WelchDirectorBuy10,000$0.93$9,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AntriaBio (OTCMKTS ANTB) News Headlines

Source:
DateHeadline
AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary AngioedemaAntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
finance.yahoo.com - October 17 at 4:46 PM
AntriaBio Appoints Nektar Therapeutics CFO to its Board of DirectorsAntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors
finance.yahoo.com - October 9 at 4:56 PM
AntriaBio Appoints Nektar Therapeutics CFO to its Board of DirectorsAntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors
finance.yahoo.com - October 9 at 4:56 PM
AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory BoardAntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board
finance.yahoo.com - October 4 at 2:22 PM
AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein InhibitorsAntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors
finance.yahoo.com - August 7 at 4:45 PM
AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101
finance.yahoo.com - July 25 at 3:46 PM
AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This MonthAntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month
finance.yahoo.com - July 17 at 4:15 PM
Nektar Therapeutics: A Sweet Or Sour Investment?Nektar Therapeutics: A Sweet Or Sour Investment?
seekingalpha.com - June 14 at 8:39 PM
ANTRIABIO, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsANTRIABIO, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - January 4 at 2:08 AM
AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common StockAntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
us.rd.yahoo.com - December 15 at 8:59 PM
ANTRIABIO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal OffiANTRIABIO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Offi
biz.yahoo.com - November 4 at 1:34 PM
ANTRIABIO, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsANTRIABIO, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 6 at 12:48 PM
ANTRIABIO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuritieANTRIABIO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securitie
biz.yahoo.com - December 10 at 1:11 PM
ANTRIABIO, INC. Files SEC form 10-Q, Quarterly ReportANTRIABIO, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 16 at 1:20 PM
ANTRIABIO, INC. Files SEC form 10-K, Annual ReportANTRIABIO, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - September 30 at 6:12 AM
ANTRIABIO, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial StANTRIABIO, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial St
biz.yahoo.com - June 29 at 9:18 AM

SEC Filings

AntriaBio (OTCMKTS:ANTB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

AntriaBio (OTCMKTS ANTB) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.